Tag Archives: NASDAQ:QURE

Leerink Partners Maintains Their Buy Rating on uniQure (QURE)

In a report issued on September 3, Joseph Schwartz from Leerink Partners maintained a Buy rating on uniQure (QURE – Research Report). The company’s shares closed last Monday at $35.24. According to TipRanks.com, Schwartz is a 4-star analyst with an

Leerink Partners Thinks uniQure’s Stock is Going to Recover

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on uniQure (QURE – Research Report) on May 27. The company’s shares closed last Friday at $34.73, close to its 52-week low of $28.58. According to TipRanks.com, Schwartz is a 4-star

Analyst Explains Why They Upgraded Their Rating on uniQure (QURE)

Mizuho Securities analyst Difei Yang upgraded uniQure (QURE – Research Report) to Buy today and set a price target of $52.00. The company’s shares closed last Wednesday at $33.69, close to its 52-week low of $28.58. According to TipRanks.com, Yang

Chardan Capital Thinks uniQure’s Stock is Going to Recover

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE – Research Report) on August 4 and set a price target of $80.00. The company’s shares closed last Monday at $41.36, close to its 52-week low of $36.20.

Credit Suisse Thinks uniQure’s Stock is Going to Recover

In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on uniQure (QURE – Research Report), with a price target of $76.00. The company’s shares closed last Friday at $41.33, close to its 52-week low of

Analysts Have Conflicting Sentiments on These Healthcare Companies: uniQure (NASDAQ: QURE) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on uniQure (QURE – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report). uniQure (QURE) uniQure received a Hold rating and a $61.00 price target from